Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

Key Points

• Clinically meaningful benefits were reported in patients receiving evenamide, improving their daily life.
• Post-hoc analyses revealed progressive long-term advantages in functioning for those on add-on treatment with evenamide.
• Adjunctive treatment with evenamide shows promise when combined with antipsychotics, including clozapine.
• This highlights the potential for novel interventions in enhancing treatment outcomes in challenging psychiatric conditions.